In a 26-year observational study of CCS reported in 2020, growth hormone use was not clearly associated with the development of a secondary cancer, with a 1.3-fold risk (95% CI 0.9–2.0) compared to non-use [131]. This evidence concerns the gene GH1 and cancer.